Gaois

This is a static copy of data that is exported from IATE on an occasional basis. It should not be assumed that information provided about an entry here will always correspond to the current version of the entry in IATE. That current version can be checked by clicking on the link on the upper right hand side of each entry. More information »

6 results

  1. SOCIAL QUESTIONS|health|health policy · SOCIAL QUESTIONS|health|pharmaceutical industry
    táirge íocshláinte lena úsáid ag an duine Reference "Rialachán (AE) Uimh. 1235/2010 lena leasaítear, maidir le cógas-aireachas ar tháirgí íocshláinte lena n-úsáid ag an duine, Rialachán (CE) Uimh. 726/2004 lena leagtar síos nósanna imeachta Comhphobail maidir le húdarú agus maoirseacht táirgí íocshláinte lena n-úsáid ag an duine agus le haghaidh úsáide tréidliachta agus lena mbunaítear Gníomhaireacht Leigheasra Eorpach, agus Rialachán (CE) Uimh. 1394/2007 maidir le táirgí íocshláinte ardteiripe, CELEX:32010R1235/GA ;Faomhadh an téarma seo mar chuid de Thionscadal Lex"
    ga
    Context 'Déantar roinnt táirgí íocshláinte lena n-úsáid ag an duine a údarú, áfach, faoi réir an choinníll go ndéanfar faireachán breise orthu. Áirítear ina measc sin gach táirge íocshláinte lena úsáid ag an duine a bhfuil substaint ghníomhach nua ann agus táirgí íocshláinte bitheolaíochta lena n-áirítear bithshamhlacha ar tosaíochtaí iad don chógas-aireachas.' Reference "Rialachán (AE) Uimh. 1235/2010 lena leasaítear, maidir le cógas-aireachas ar tháirgí íocshláinte lena n-úsáid ag an duine, Rialachán (CE) Uimh. 726/2004 lena leagtar síos nósanna imeachta Comhphobail maidir le húdarú agus maoirseacht táirgí íocshláinte lena n-úsáid ag an duine agus le haghaidh úsáide tréidliachta agus lena mbunaítear Gníomhaireacht Leigheasra Eorpach, agus Rialachán (CE) Uimh. 1394/2007 maidir le táirgí íocshláinte ardteiripe, CELEX:32010R1235/GA"
    Humanarzneimittel
    de
    medicinal product for human use
    en
    Definition in the framework of Directive 2001/83/EC, any substance or combination of substances presented as having properties for treating or preventing disease in human beings; or any substance or combination of substances which may be used in or administered to human beings either with a view to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or to making a medical diagnosis Reference "Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use, CELEX:02001L0083-20121116/EN"
    Comment "See also:- IATE:773210 ""veterinary medicinal product; medicinal product for veterinary use"" - IATE:793544 ""medicinal product"""
    médicament à usage humain
    fr
  2. EUROPEAN UNION|EU institutions and European civil service|EU institution|European Commission · SOCIAL QUESTIONS|health|pharmaceutical industry · EUROPEAN UNION|EU institutions and European civil service|EU office or agency|committee (EU)|standing committee (EU)
    an Buanchoiste um Tháirgí Íocshláinte lena nÚsáid ag an Duine Reference "Rialachán (AE) Uimh. 536/2014 maidir le trialacha cliniciúla ar tháirgí íocshláinte lena n-úsáid ag an duine"
    ga
    Context 'Beidh an Buanchoiste um Tháirgí Íocshláinte lena nÚsáid ag an Duine, arna bhunú le Treoir 2001/83/CE, de chúnamh don Choimisiún.' Reference "Rialachán (AE) Uimh. 536/2014 maidir le trialacha cliniciúla ar tháirgí íocshláinte lena n-úsáid ag an duine"
    Ständiger Ausschuss für Humanarzneimittel
    de
    Standing Committee on Medicinal Products for Human Use | Committee for Adaptation to Technical Progress of the Directives on the Removal of Technical Barriers in the Proprietary Medicinal Products Sector
    en
    Comment UPDATED: neq: 19/3/02
    comité permanent des médicaments à usage humain
    fr
  3. SOCIAL QUESTIONS|health|pharmaceutical industry · EUROPEAN UNION|EU institutions and European civil service|EU office or agency|European Medicines Agency · EUROPEAN UNION|EU institutions and European civil service|EU office or agency|committee (EU)
    an Coiste um Tháirgí Íocshláinte lena nÚsáid ag an Duine Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    Ausschuss für Humanarzneimittel
    de
    Definition Teil der Agentur, zuständig für die Formulierung des Gutachtens der Agentur zu allen Fragen bezüglich der Zulässigkeit der nach dem zentralisierten Verfahren eingereichten Dossiers, der Erteilung, Änderung, Aussetzung oder des Widerrufs einer Genehmigung für das Inverkehrbringen eines Humanarzneimittels [...] sowie bezüglich der Pharmakovigilanz Reference "VO 726/2004 Gemeinschaftsverfahren für die Genehmigung und Überwachung von Human- und Tierarzneimitteln und zur Errichtung einer Europäischen Arzneimittel-Agentur, Art.5 (ABl. L_136/2004, S.1) CELEX:32004R0726/DE"
    Comment DIV: RSZ 03/12/2002;UPDATED: AIH 28/05/2004; UPD: CHO 26/06/07
    Committee for Medicinal Products for Human Use | CHMP | Committee for Proprietary Medicinal Products | CPMP | Committee on Medicinal Products for Human Use
    en
    Definition Committee attached to the European Medicines Agency and responsible for drawing up the Agency's opinions on, inter alia, the granting, variation, suspension or revocation of an authorisation to place a medicinal product for human use on the market, and pharmacovigilance. Reference "Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency"
    comité des médicaments à usage humain | CHMP | CPMP | Comité des spécialités pharmaceutiques
    fr
    Definition "Comité relevant de l'Agence européenne des médicaments [IATE:843722 ], chargé de formuler l'avis de l'Agence sur, entre autres, la recevabilité, l'octroi, la modification, la suspension ou le retrait d'une autorisation de mise sur le marché d'un médicament à usage humain, ainsi que de la pharmacovigilance." Reference "CELEX:32004R0726/FR"
    CHMP
    mul
  4. SOCIAL QUESTIONS|health|pharmaceutical industry
    Rialachán (AE) Uimh. 536/2014 maidir le trialacha cliniciúla ar tháirgí íocshláinte lena n-úsáid ag an duine Reference "Rialachán (AE) Uimh. 536/2014 maidir le trialacha cliniciúla ar tháirgí íocshláinte lena n-úsáid ag an duine, agus lena n-aisghairtear Treoir 2001/20/CE, CELEX:2014R0536-20140527/GA Faomhadh an téarma seo mar chuid de Thionscadal Lex"
    ga
    Clinical Trial Regulation | Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use
    en
    Definition Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use Reference "Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC (Text with EEA relevance) "
  5. SOCIAL QUESTIONS|health|pharmaceutical industry
    táirge íocshláinte ar oideas liachta ‘srianta’, a chuirtear in áirithe lena n‑úsáid i sainréimsí áirithe Reference "Togra le haghaidh Treoir maidir le Cód an Aontais a bhaineann le táirgí íocshláinte lena n‑úsáid ag an duine, agus lena n‑aisghairtear Treoir 2001/83/CE agus Treoir 2009/35/CE, CELEX:52023PC0192/GA Faomhadh an téarma seo mar chuid de Thionscadal Lex"
    ga
    medicinal product on ‘restricted’ medical prescription, reserved for use in certain specialised areas
    en
  6. SOCIAL QUESTIONS|health|pharmaceutical industry
    táirge íocshláinte dílleachtach Reference Comhairle-GA
    ga
    Context """Ba cheart gur de réir oibleagáidí ar leith a dhéanfaí údaruithe margaíochta den sórt sin a dheonú. Ba cheart go mbeadh sna catagóirí táirgí íocshláinte lena n-úsáid ag an duine lena mbaineann na táirgí íocshláinte, lena n-áirítear táirgí íocshláinte dílleachtacha, a bhfuil sé mar aidhm leo galair thromchúiseacha dhíblitheacha nó is baol báis a chóireáil nó a chosc...""" Reference "Rialachán (AE) 2019/5 ó Pharlaimint na hEorpa agus ón gComhairle"
    druga dílleachta Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    táirge íocshláinte dílleachta Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    táirge íocshláinte dílleachtach lena úsáid ag an duine Reference Téarmeolaithe COM-GA
    ga
    Arzneimittel für seltene Leiden | Orphan-Arzneimittel | Humanarzneimittel für seltene Leiden
    de
    Definition ein nach den Bestimmungen der Verordnung (EG) Nr. 141/2000 ausgewiesenes Arzneimittel (Orphan medicinal product) Reference "Verordnung (EG) Nr. 141/2000, Artikel 2 Buchstabe b CELEX:32000R0141/DE"
    Comment "Gemäß der Verordnung (EG) Nr. 141/2000 sind dies nicht nur Arzneimittel für seltene Krankheiten (Kriterium: 5 Erkrankungen auf 10.000 Personen), sondern auch aus anderen Gründen nicht-rentable Arzneimittel (vgl. Artikel 3 Absatz 1 Buchstabe a).Die richtige Bezeichnung für ""Orphan disease""/""maladie orpheline"" im Deutschen lautet ""Waisenkrankheit"" oder ""Orphan-Krankheit"" (siehe IATE:139134 ). ""Seltene Krankheit"" steht dagegen für ""rare disease""/""maladie rare"" IATE:883096 ."
    orphan medicinal product | orphan medicine | orphan drug | orphan medicinal product for human use
    en
    Definition medicinal product intended for the diagnosis, prevention or treatment of a life-threatening or very serious condition, where no other such product exists because it would not be economically viable to develop one and/or because the condition is rare Reference "Council-EN based on Regulation (EC) No 141/2000 on orphan medicinal products, Article 3 CELEX:02000R0141-20190726"
    Comment "The regulatory designation as an 'orphan medicinal product' is associated with incentives intended to promote the development of such medicines.See also:- orphan disease, IATE:139134 - rare disease, IATE:883096<><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>"
    médicament orphelin | médicament orphelin à usage humain
    fr
    Definition médicament destiné à traiter une maladie grave et rare, à laquelle les investisseurs s'intéressent peu Reference "Délégation générale à la langue française et aux langues de France (DGLFLF), FranceTerme, http://www.culture.fr/franceterme/result?francetermeSearchTerme=medicament+orphelin&francetermeSearchDomaine=0&francetermeSearchSubmit=rechercher&action=search [22.10.2018]"
    Comment "Dans le cadre juridique de l'Union européenne, un médicament orphelin est un médicament ainsi désigné dans les conditions prévues par le règlement n° 141/2000 concernant les médicaments orphelins. Conformément audit règlement, un médicament obtient la désignation de médicament orphelin si son promoteur peut établir:a) qu'il est destiné au diagnostic, à la prévention ou au traitement d'une affection entraînant une menace pour la vie ou une invalidité chronique ne touchant pas plus de cinq personnes sur dix mille dans la Communauté, au moment où la demande est introduite, ouqu'il est destiné au diagnostic, à la prévention ou au traitement, dans la Communauté, d'une maladie mettant la vie en danger, d'une maladie très invalidante ou d'une affection grave et chronique, et qu'il est peu probable que, en l'absence de mesures d'incitation, la commercialisation de ce médicament dans la Communauté génère des bénéfices suffisants pour justifier l'investissement nécessaireetb) qu'il n'existe pas de méthode satisfaisante de diagnostic, de prévention ou de traitement de cette affection ayant été autorisée dans la Communauté, ou, s'il en existe, que le médicament en question procurera un bénéfice notable à ceux atteints de cette affection.Conseil-FR, d'après le règlement n° 141/2000 concernant les médicaments orphelins, CELEX:02000R0141-20090807/FR Voir aussi:- maladie orpheline [IATE:139134 ]- maladie rare [IATE:883096 ]"